Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma

Clinical Cancer Research

Volumn 20, Issue 24, 2014, Pages 6551-6558

  Capelletti, Marzia ^a   Dodge, Michael E ^a   Ercan, Dalia ^a   Hammerman, Peter S ^a   Park, Seung Il ^b   Kim, Jhingook ^c   Sasaki, Hidefumi ^d   Jablons, David M ^e   Lipson, Doron ^f   Young, Lauren ^f   Stephens, Phil J ^f   Miller, Vincent A ^f   Lindeman, Neal I ^g   Munir, Kiara J ^g   Richards, William G ^g   Jänne, Pasi A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b University of Ulsan College of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f FOUNDATION MEDICINE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GEFITINIB; INTERLEUKIN 3; 3-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-1-(6-(4-(4-ETHYLPIPERAZIN-1-YL)-PHENYLAMINO)PYRIMIDIN-4-YL)-1-METHYLUREA; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; PYRIMIDINE DERIVATIVE; TACC3 PROTEIN, HUMAN;

ARTICLE; ASIAN; BIOASSAY; CANCER RESISTANCE; CAUCASIAN; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; ETHNICITY; FEMALE; FIBROBLAST GROWTH FACTOR RECEPTOR 3 GENE; GENE EXPRESSION; GENE FUSION; GENE IDENTIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENETIC SCREENING; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; SENSITIVITY ANALYSIS; TRANSFORMING ACIDIC COILED COIL 3 GENE; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; BIOLOGY; CANCER STAGING; CELL TRANSFORMATION; DRUG RESISTANCE; GENE FREQUENCY; GENE TRANSLOCATION; GENETICS; GENOMICS; LUNG TUMOR; PATHOLOGY; RISK FACTOR;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE FREQUENCY; GENOMICS; HUMANS; LUNG NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PHENYLUREA COMPOUNDS; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RISK FACTORS; TRANSLOCATION, GENETIC;

EID: 84919724844     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1337     Document Type: Article

References (41)

1. Paez JG, Janne PA, Lee JC, Tracy S., Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
2. Soda M, Choi YL, Enomoto M, Takada S., Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
3. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
4. Shaw AT, Kim DW, Nakagawa K, Seto T., Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
5. Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, Smit E., Rodriguez JA, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006; 12:6049-55.
6. Lee SM, Khan I, Upadhyay S., Lewanski C, Falk S, Skailes G., et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a doubleblind, placebo-controlled, phase 3 trial. Lancet Oncol 2012;13: 1161-70.
7. Rikova K, Guo A, Zeng Q., Possemato A, Yu J, Haack H., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203.
8. Lipson D, Capelletti M, Yelensky R., Otto G, Parker A, Jarosz M., et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382-4.
9. Lin L, Asthana S, Chan E., Bandyopadhyay S, Martins MM, Olivas V, et al. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci U S A 2014; 111:E748-57.
10. Cardarella S, Ogino A, Nishino M., Butaney M, Shen J, Lydon C., et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013;19: 4532-40.
11. Mazieres J, Peters S, Lepage B., Cortot AB, Barlesi F, Beau-Faller M, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013;31: 1997-2003.
12. Yano T, Miura N, Takenaka T., Haro A, Okazaki H, Ohba T., et al. Neversmoking nonsmall cell lung cancer as a separate entity: clinicopath-ologic features and survival. Cancer 2008;113:1012-8.
13. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 2007;25:561-70.
14. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers - a different disease. Nat Rev Cancer 2007;7:778-90.
15. Vaishnavi A, Capelletti M, Le AT, Kako S., Butaney M, Ercan D, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 2013;19:1469-72.
16. Drilon A, Wang L, Hasanovic A., Suehara Y, Lipson D, Stephens P., et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013;3:630-5.
17. Janne PA, Borras AM, Kuang Y, Rogers AM, Joshi VA, Liyanage H, et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 2006;12:751-8.
18. Takeuchi K, Choi YL, Soda M, Inamura K., Togashi Y, Hatano S, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14:6618-24.
19. Singh D, Chan JM, Zoppoli P, Niola F., Sullivan R, Castano A, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012;337:1231-5.
20. Gnirke A, Melnikov A, Maguire J., Rogov P, LeProust EM, Brockman W, et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 2009; 27:182-9.
21. Li H, Handsaker B, Wysoker A., Fennell T, Ruan J, Homer N., et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009;25:2078-9.
22. McKenna A, Hanna M, Banks E., Sivachenko A, Cibulskis K, Kernytsky A., et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20:1297-303.
23. He M, Capelletti M, Nafa K., Yun CH, Arcila ME, Miller VA, et al. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res 2012;18:1790-7.
24. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507: 315-22.
25. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013;3:636-47.
26. Shigematsu H, Lin L, Takahashi T., Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
27. Janne PA, Wang X, Socinski MA, Crawford J., Stinchcombe TE, Gu L, et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol 2012;30:2063-9.
28. Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 2013;5:216ra177.
29. Riely GJ, Kris MG, Rosenbaum D, Marks J., Li A, Chitale DA, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731-4.
30. Hernandez L, Pinyol M, Hernandez S., Bea S, Pulford K, Rosenwald A., et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 1999;94:3265-8.
31. Togashi Y, Soda M, Sakata S., Sugawara E, Hatano S, Asaka R., et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PloS ONE 2012;7:e31323.
32. Lanzi C, Cassinelli G, Nicolini V., Zunino F. Targeting RET for thyroid cancer therapy. Biochem Pharmacol 2009;77:297-309.
33. Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 2005;16: 441-67.
34. Berger AH, Imielinski M, Duke F., Wala J, Kaplan N, Shi GX, et al. Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene 2014;33:4418-23.
35. Gomez-Segui I., Makishima H, Jerez A., Yoshida K, Przychodzen B, Miyano S., et al. Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies. Leukemia 2013;27:1943-6.
36. Aoki Y, Niihori T, Banjo T., Okamoto N, Mizuno S, Kurosawa K., et al. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am J Hum Genet 2013;93:173-80.
37. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013;22:795-803.
38. Kim Y, Hammerman PS, Kim J, Yoon JA, Lee Y., Sun JM, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol 2014;32:121-8.
39. Imielinski M, Berger AH, Hammerman PS, Hernandez B., Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150:1107-20.
40. Arai Y, Totoki Y, Hosoda F., Shirota T, Hama N, Nakamura H., et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 2014; 59:1427-34.
41. Sequist LV, Cassier P, Varga A., Tabernero J, Schellens JH, Delord J, et al editors. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 April 5-9; San Diego (CA): AACR; 2014. Abstract nr 326.